MedicalExpo e-Magazine, a trade publication aimed at medical professionals, published a featured article on April 20, 2026 framing mold toxicity as an "expanding clinical frontier" in inflammatory and immune disorders. The piece argues that emerging evidence and clinical reports increasingly point to mold exposure as a driver of complex inflammatory syndromes, and calls for sharper diagnostics and integrative treatment in primary care.
The article centers on Chronic Inflammatory Response Syndrome (CIRS), describing it as a multi-system inflammatory condition triggered by biotoxins in genetically susceptible individuals. It cites the same biomarker panel long associated with the Shoemaker Protocol — C4a, TGF-β1, and MMP-9 — alongside HLA-DR genotyping and detailed environmental history-taking as diagnostic tools clinicians should consider. Mold-derived biotoxins, the piece notes, can dysregulate innate immune signaling, disrupt hormones, and impair mitochondrial function.
MedicalExpo points out that medical and scientific journals have been documenting a rising prevalence of mold-related health problems since at least 2007, and references public discussion sparked by Canadian psychologist Jordan Peterson's account of mold-linked symptoms. While the article acknowledges ongoing controversy in mainstream medicine, it argues the underlying pathophysiology of biotoxin-driven illness warrants serious clinical evaluation.